Synonyms: GFT-505 | GFT505 | Iqirvo®
elafibranor is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Elafibranor (GFT-505) is a PPARα/δ agonist.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Blair HA. (2024)
Correction: Elafibranor: First Approval. Drugs, 84 (9): 1165. [PMID:39240532] |
2. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. (2013)
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care, 36 (10): 2923-30. [PMID:23715754] |
3. Cariou B, Zaïr Y, Staels B, Bruckert E. (2011)
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care, 34 (9): 2008-14. [PMID:21816979] |
4. Sahebkar A, Chew GT, Watts GF. (2014)
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother, 15 (4): 493-503. [PMID:24428677] |